La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Eagle Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG Eagle Pharmaceuticals' est Mike Graves, nommé en Jan2023, a un mandat de 1.58 ans. détient directement 0.08% des actions de la société, d'une valeur de $ 46.93K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.1 ans et 7.8 ans.

Informations clés

Mike Graves

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	1.6yrs
Propriété du PDG	0.08%
Durée moyenne d'occupation des postes de direction	2.1yrs
Durée moyenne du mandat des membres du conseil d'administration	7.8yrs

Mises à jour récentes de la gestion

Recent updates

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16

Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Jul 06

Eagle Pharmaceuticals: A Potential Reopening Play

Jun 16

PDG

Mike Graves (61 yo)

1.6yrs

Titularisation

US$391,026

Compensation

Mr. Michael Graves, also known as Mike, is Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. from 2023. He had been the Independent Chairman of Eagle Pharmaceuticals Inc. since June 2016 u...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	1.6yrs	US$391.03k	0.080% $ 47.7k
Steven Ratoff	Interim CFO	less than a year	US$331.03k	0.21% $ 125.9k
Daniel O'Connor	Executive VP	7.3yrs	pas de données	pas de données
Valentin Curt	Senior Vice President of Clinical Drug Development	3.8yrs	pas de données	pas de données
Gaozhong Zhu	Senior Vice President of Pharmaceutical Development	3.8yrs	pas de données	pas de données
Debra Hussain	Senior VP & Head of Commercial	2.1yrs	pas de données	pas de données
Reed McClung	Executive Vice President of Oncology Business Development	1.6yrs	pas de données	pas de données

2.1yrs

Durée moyenne de l'emploi

58.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de EGRX est considérée comme expérimentée (ancienneté moyenne 2.1 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	10.8yrs	US$391.03k	0.080% $ 47.7k
Steven Ratoff	Interim CFO	17.4yrs	US$331.03k	0.21% $ 125.9k
Richard Edlin	Independent Director	7.4yrs	US$312.28k	0.17% $ 104.0k
Robert Glenning	Independent Director	8.1yrs	US$324.78k	0% $ 0
Jennifer Simpson	Lead Independent Director	5yrs	US$308.53k	0% $ 0
Luciana Borio	Independent Director	3.3yrs	US$308.53k	0% $ 0

7.8yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de EGRX sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).

Eagle Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Founder recently sold US$931k worth of stock

Founder notifies of intention to sell stock

Recent updates

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. and Curia Global, Inc. Enters into Settlement Agreement in AAA Case No. 01-23-0000-2937

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals, Inc. announced delayed annual 10-K filing

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

New minor risk - Financial data availability

Investor sentiment improves as stock rises 19%

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment deteriorates as stock falls 32%

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Founder notifies of intention to sell stock

Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc

Founder notifies of intention to sell stock

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Investor sentiment deteriorates as stock falls 18%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Eagle Pharmaceuticals, Inc. Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, A Novel First-In-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Growth-Defensive Index

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

New major risk - Revenue and earnings growth

Eagle Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (Qidp) and Fast-Track Designation for Cal02, Providing Five-Year Exclusivity Extension

Founder recently sold US$931k worth of stock

Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 20%

Eagle Pharmaceuticals, Inc. Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy

Consensus forecasts updated

Insufficient new directors

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Independent Director recently sold US$211k worth of stock

Insufficient new directors

U.S. Court of Appeals for the Federal Circuit Affirms the U.S. District Court for the District of Delaware’s Decision That Eagle Pharmaceuticals, Inc.'s Vasopressin Product Does Not Infringe on Any of the Patents Asserted by Par Pharmaceutical, Inc

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Consensus revenue estimates fall by 21%

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Price target decreased to US$43.00

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Eagle Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Michael Moran Separates as Executive Vice President, Chief Commercial Officer of Eagle Pharmaceuticals, Inc

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc., Annual General Meeting, Jul 28, 2022

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders.

Eagle Pharmaceuticals, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, A Beta-1 Adrenergic Blocker

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 20% undervalued

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders for €89.8 million.

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH).

Eagle Pharmaceuticals, Inc. Provides Earnings Guidance for the First Quarter of 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Eagle Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 07, 2022

Eagle Pharmaceuticals, Inc. Announces Commercial Availability of PEMFEXY™